FDA seeks active system for monitoring adverse events

被引：0
|
作者：
Wechsler, Jill
机构：
来源：
BIOPHARM INTERNATIONAL | 2008年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：14 / +
页数：2
相关论文
共 50 条
  • [41] Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
    Shu, Yamin
    He, Xucheng
    Wu, Pan
    Liu, Yanxin
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [42] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [43] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    HELIYON, 2024, 10 (14)
  • [44] Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
    Pan, Xianglin
    Xiao, Xiangtian
    Ding, Yiling
    Shu, Yamin
    Zhang, Wenting
    Huang, Liu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System DatabaseA Disproportionality Analysis
    Behrooz K. Shamloo
    Pankdeep Chhabra
    Andrew N. Freedman
    Arnold Potosky
    Jennifer Malin
    Sheila Weiss Smith
    Drug Safety, 2012, 35 : 507 - 518
  • [46] Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system
    Wang, Xiaomeng
    Wang, Jimei
    Liu, Fang
    Zhang, Kexin
    Zhao, Min
    Xu, Lin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [47] Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
    Li, Liangxia
    Xu, Qianqian
    Liu, Yarui
    Pang, Liangfang
    Cui, Zhou
    Lu, Yuanyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [48] Assessing taxane-associated adverse events using the FDA adverse event reporting system database
    Lao, Dong-Hui
    Chen, Ye
    Fan, Jun
    Zhang, Jian-Zhong
    CHINESE MEDICAL JOURNAL, 2021, 134 (12) : 1471 - 1476
  • [49] Comparative Analysis of Psychiatric Adverse Events of Brivaracetam and Levetiracetam Using the FDA Adverse Event Reporting System
    Porwal, Mokshal H.
    Shah, Ipsit
    Shah, Aneri N.
    Obeidat, Ahmed Z.
    ANNALS OF NEUROLOGY, 2022, 92 : S87 - S88
  • [50] Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System
    Zhao, Dehua
    Long, Xiaoqing
    Wang, Jisheng
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 599 - 605
12345